Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 6Terminated 4Unknown 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

NSCLC 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Axitinib × Thoracic × Clear all
NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2/3 Unknown
20 enrolled
Thoracic

NSCLC

NCT04459663 2020-07-07

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Sun Yat-sen University

Phase 2 Unknown
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡